Core Insights - In 2025, Guangdong Tianenkang Pharmaceutical Co., Ltd. (referred to as "Tianenkang") is committed to the core philosophy of "putting investors first," focusing on information disclosure, corporate governance, market value management, and social responsibility to enhance compliance and steadily increase corporate value [1][2] Group 1: Corporate Achievements - Tianenkang has received multiple authoritative awards for its outstanding performance in innovation research and development, market value management, corporate governance, and ESG practices, reflecting broad market recognition of its high-quality development [1] - On December 15, 2025, Tianenkang was included in the sample range of the CSI 1000 Index, indicating robust fundamental operations and good market liquidity, which marks its investment value recognized by index compilers [1] - The company launched an employee stock ownership plan on August 5, 2025, to stimulate internal motivation and inject strong momentum for long-term development [1] Group 2: Investor Relations Management - Tianenkang has established multiple communication channels for investor relations, holding two performance briefings and receiving over 200 institutional visits throughout the year, including six research meetings with various institutions [2] - The company responded to 51 investor inquiries on the interactive platform, focusing on key investor concerns such as CKBA clinical progress and product development pipeline [2] - In 2025, Tianenkang laid a solid foundation for high-quality development through precise information disclosure, an efficient governance system, innovative market value management, and solid ESG practices, with plans to deepen investor communication and optimize capital operation strategies [2]
泰恩康2025年资本市场认可度再创新高